Schlagwort: neurological diseases
The Biotech IP Flip: Scaling Up Instead of Selling
Many European biotech companies still view the U.S. market primarily as a future exit channel. Yet it can be leveraged much earlier - not...
Can biopharma’s drug-focused R&D strategy remain profitable?
Since the 1990s, there has been a shift in focus within pharmaceutical R&D. It resulted in placing greater emphasis on areas such as cancer,...